Status:

COMPLETED

Blood Loss During Cesarean Delivery in Placenta Previa Patients

Lead Sponsor:

Cairo University

Conditions:

Placenta Previa

Eligibility:

FEMALE

18-40 years

Phase:

PHASE4

Brief Summary

To compare the efficacy and safety profile of intravenous tranexamic acid versus intrauterine misoprostol in reducing the blood loss during and after cesarean delivery in pregnant women diagnosed with...

Detailed Description

Placenta previa is defined as complete or partial covering of the internal os of the cervix with the placenta, at more than 16 weeks of gestation. It affects 0.3% to 2% of pregnancies in the third tri...

Eligibility Criteria

Inclusion

  • Parity: primigravida or multigravida.
  • Gestational age: ≥ 36 weeks (confirmed by the first day of the last menstrual period or first trimester ultrasound scan).
  • Candidate for termination of pregnancy by cesarean delivery.
  • Singleton living healthy normally growing fetus.
  • Cesarean delivery under spinal anesthesia.
  • Pregnancies complicated with placenta previa diagnosed preoperatively by ultrasonography (placenta previa was defined as placenta partially or totally covers the cervix)

Exclusion

  • Patients diagnosed with morbidly adherent placenta.
  • Placenta previa cases requiring cesarean hysterectomy in the primary surgery.
  • Patients with preoperative anemia (Hemoglobin \<9 gm/dl).
  • History of thromboembolic event.
  • Known allergy to tranexamic acid or prostaglandins.
  • Bronchial asthma or other contraindications of misoprostol.
  • Patients with other risk factors of postpartum hemorrhage (e.g., polyhydramnios, fetal macrosomia, uterine fibroid).
  • Patients known to have bleeding tendency (e.g., those receiving anticoagulation, patients with thrombocytopenia, factor VIII or IX deficiency or Von Willebrand's disease).
  • More than 2 previous cesarean deliveries procedures.
  • Prolonged procedure (more than 2 hours from skin incision to skin closure).
  • Concomitant maternal medical disorders (either chronic or pregnancy induced)

Key Trial Info

Start Date :

May 4 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 5 2023

Estimated Enrollment :

81 Patients enrolled

Trial Details

Trial ID

NCT05340205

Start Date

May 4 2022

End Date

January 5 2023

Last Update

January 6 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kasralainy Cairo University

Giza, Egypt